Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug-Drug-Gene Interaction Predictions
Within this repository, we distribute a whole-body parent-metabolite PBPK model of clopidogrel and its metabolites clopidogrel carboxylic acid, clopidogrel acyl glucuronide, 2-oxo-clopidogrel, as well as the active metabolite clopidogrel thiol H4. The model has been carefully developed using a large number of published clinical studies and the predictive performance of the model was evaluated within our DDI network.
The model is split into two files:
- Clopidogrel-Model: Contains simulations of the published clinical studies used during model development, including the respective observed data digitized from literature.
- Clopidogrel-CYP2C19-DGI: Contains simulations describing the effect of different CYP2C19 phenotypes on the pharmacokinetics of clopidogrel and clopidogrel thiol H4.
For further details, quantitative model evaluation, sensitivity analysis and extensive documentation please refer to [1].
PK-Sim Version 9.1
Everyone interacting in the Open Systems Pharmacology community (codebases, issue trackers, chat rooms, mailing lists etc...) is expected to follow the Open Systems Pharmacology code of conduct.
We encourage contribution to the Open Systems Pharmacology community. Before getting started please read the contribution guidelines. If you are contributing code, please be familiar with the coding standard.
The model code is distributed under the GPLv2 License.